Atrial Fibrillation: A Real-Life Observational Study in the Quebec Population

被引:6
|
作者
Guertin, Jason R. [1 ]
Dorais, Marc [2 ]
Khairy, Paul [3 ]
Sauriol, Luc [4 ]
Matteau, Alexis [1 ]
Poulin, Frederic [3 ]
Talajic, Mario [3 ]
Roy, Denis [3 ]
LeLorier, Jacques [1 ]
机构
[1] Ctr Hosp Univ Montreal, Res Ctr, Pharmacoecon & Pharmacoepidemiol Res Unit, Montreal, PQ H2W 1T7, Canada
[2] Statsciences Inc, Notre Dame Lile Perrot, PQ, Canada
[3] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada
[4] Sanofi Aventis Inc, Laval, PQ, Canada
关键词
CHRONIC DISEASE SCORE; QUALITY-OF-LIFE; RHYTHM-CONTROL; CANADIAN REGISTRY; HEART-FAILURE; PROGRESSION; CLAIMS; RISK;
D O I
10.1016/j.cjca.2011.03.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Atrial fibrillation (AF) is the most common cardiac arrhythmia and has been associated with heart failure, stroke, and mortality. The prevalence of AF is expected to rise with the aging population. Our objectives were to characterize the Quebec AF patient population at the time of diagnosis of AF, quantify medical resource use prior to and after the initial diagnosis of AF, and determine overall survival. Methods: A retrospective cohort study was undertaken using the Regie de l'Assurance Maladie du Quebec databases to evaluate patients diagnosed with AF between January 1, 1998, and April 30, 2009. Results: A total of 64,157 patients were included in our study population. At the time of diagnosis of AF, patients also suffered from several diseases, including heart failure (15.8%) and angina pectoris (15.1%). Compared with the year prior to AF diagnosis, in the year after AF diagnosis patients were more frequently hospitalized (1.5 vs 1.1 hospitalizations) and for longer periods (5.6 vs 3.3 days), and had more outpatient visits (12.(vs 11.7). Survival rapidly decreased during the first 60 days (60-day mortality, 6.1%) and steadily declined thereafter, with mortality rates of 14.7% and 36.8% at 1 and 5 years, respectively. Conclusion: At the time of diagnosis of AF, patients often suffer from several comorbidities. Diagnosis of AF is associated with an increase in medical resource use and higher mortality rates, particularly within the first 60 days.
引用
收藏
页码:794 / 799
页数:6
相关论文
共 50 条
  • [1] Atrial Fibrillation and Cardiovascular Comorbidities, Survival and Mortality: A Real-Life Observational Study
    Luis Clua-Espuny, Jose
    Panisello-Tafalla, Anna
    Lopez-Pablo, Carlos
    Lechuga-Duran, Inigo
    Bosch-Princep, Ramon
    Lucas-Noll, Jorgina
    Gonzalez-Henares, Antonia
    Queralt-Tomas, Lluisa
    Ripolles-Vicente, Rosa
    Calduch-Noll, Cristina
    Gonzalez-Rojas, Nuria
    Gallofre-Lopez, Miguel
    [J]. CARDIOLOGY RESEARCH, 2014, 5 (01) : 12 - 22
  • [2] Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population
    Cerda, Maria
    Cerezo-Manchado, Juan J.
    Johansson, Erik
    Martinez, Fernanda
    Fernandez, Mariana
    Varela, Ana
    Rodriguez, Saray
    Bosch, Francesc
    Santamaria, Amparo
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (03) : 165 - 178
  • [3] REal-LIfe Evidence of stroke prevention in patients with atrial Fibrillation - The RELIEF study
    Coleman, Craig I.
    Antz, Matthias
    Ehlken, Birgit
    Evers, Thomas
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 203 : 882 - 884
  • [4] Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation
    Baron-Esquivias, Gonzalo
    Fernandez-Aviles, Francisco
    Atienza, Felipe
    Pastor Pueyo, Pablo
    Toro, Rocio
    Sanmartin Fernandez, Marcelo
    [J]. EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2015, 13 (04) : 341 - 353
  • [5] Registries in Atrial Fibrillation: From Trials to Real-Life Clinical Practice
    Mazurek, Michal
    Huisman, Menno V.
    Lip, Gregory Y. H.
    [J]. AMERICAN JOURNAL OF MEDICINE, 2017, 130 (02): : 135 - 145
  • [6] Anticoagulation in Real-Life Patients with Atrial Fibrillation: Impact of Renal Disease
    Undas, Anetta
    [J]. ANATOLIAN JOURNAL OF CARDIOLOGY, 2023, 27 (01): : 54 - 55
  • [7] DABIGATRAN TROUGH AND PEAK LEVELS IN "REAL-LIFE" PATIENTS WITH ATRIAL FIBRILLATION
    Sinigoj, P.
    Malmstrom, R. E.
    Vene, N.
    Bozic-Mijovski, M.
    Pohanka, A.
    Antovic, J. P.
    Mavri, A.
    [J]. THROMBOSIS RESEARCH, 2016, 141 : S2 - S2
  • [8] Atrial fibrillation and stroke risk prevention in real-life clinical practice
    Tay, Kok Hoon
    Lip, Gregory Y. H.
    Lane, Deirdre A.
    [J]. THROMBOSIS AND HAEMOSTASIS, 2009, 101 (03) : 415 - 416
  • [9] Electrical cardioversion for atrial fibrillation: outcomes in 'real-life' clinical practice
    Berry, C
    Stewart, S
    Payne, EM
    McArthur, JD
    McMurray, JJV
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2001, 81 (01) : 29 - 35
  • [10] Real-Life Incident Atrial Fibrillation in Outpatients with Coronary Artery Disease
    Ninni, Sandro
    Lemesle, Gilles
    Meurice, Thibaud
    Tricot, Olivier
    Lamblin, Nicolas
    Bauters, Christophe
    [J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (08) : 1 - 11